1. Biochemical and Stone-Risk Profiles With Topiramate Treatment
Brian J. Welch, MD, Dion Graybeal, MD, Orson W. Moe, MD, Naim M. Maalouf, MD, Khashayar Sakhaee, MD 
American Journal of Kidney Diseases 
Volume 48, Issue 4, Pages (October 2006)
DOI: /j.ajkd
Copyright © 2006 National Kidney Foundation, Inc. Terms and Conditions

2. Fig 1
Urinary pH and urinary citrate excretion (cross-sectional study). Horizontal lines indicate mean values. Hypocitraturia is defined as 24-hour urinary citrate excretion less than 320 mg/d Abbreviation: TPM, topiramate.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2006 National Kidney Foundation, Inc. Terms and Conditions

3. Fig 2
RSRs and undissociated uric acid excretion (cross-sectional study). Vertical bars, mean ± SD; white bars, control group; black bars, topiramate group. *P < compared with the control group.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2006 National Kidney Foundation, Inc. Terms and Conditions

4. Fig 3
Changes in (A) urinary pH and (B) urinary citrate excretion (milligrams per day) between baseline and after 3 months of topiramate treatment (short-term longitudinal study). Horizontal lines indicate mean values. Hypocitraturia is defined as 24-hour urinary citrate excretion less than 320 mg/d Abbreviation: TPM, topiramate.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2006 National Kidney Foundation, Inc. Terms and Conditions

5. Fig 4
Change in RSRs for (A) calcium oxalate and (B) brushite stones between baseline and after 3 months of topiramate treatment (short-term longitudinal study). Horizontal lines indicate mean values. Abbreviation: TPM, topiramate.
American Journal of Kidney Diseases  , DOI: ( /j.ajkd )
Copyright © 2006 National Kidney Foundation, Inc. Terms and Conditions